Form 4: NewAmsterdam Pharma CAO Sells Shares After Option Exercise

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, exercised stock options and subsequently sold a significant portion of the acquired ordinary shares in late December 2025.

Summary

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NAMS), engaged in multiple transactions involving the exercise of stock options and the sale of ordinary shares.
• On December 23, 2025, Kooij exercised options to acquire 75,117 ordinary shares at an exercise price of $10.00 per share and subsequently sold all 75,117 shares at a weighted average price of $36.21 per share.
• On December 24, 2025, Kooij exercised options to acquire 26,011 ordinary shares at an exercise price of $10.00 per share and subsequently sold all 26,011 shares at a weighted average price of $35.68 per share.
• On December 26, 2025, Kooij exercised options to acquire 38,872 ordinary shares at an exercise price of $10.00 per share and an additional 5,000 ordinary shares at an exercise price of $10.90 per share.
• On December 26, 2025, Kooij sold a total of 43,872 ordinary shares (comprising the 38,872 and 5,000 shares acquired on the same day) at a weighted average price of $35.30 per share.
• Following these transactions, Kooij directly beneficially owns 15,000 ordinary shares and 218,134 derivative securities (options to buy ordinary shares).

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving option exercises and subsequent share sales. While profitable for the executive, the selling aspect can be viewed neutrally to slightly negatively by the market, as it reduces insider ownership. The transactions were made pursuant to a Rule 10b5-1 plan, suggesting they were pre-scheduled rather than reactive.

Positives

• The Chief Accounting Officer realized significant gains by exercising options at $10.00-$10.90 and selling shares at $35.30-$36.21, indicating a profitable outcome for the insider.
• The exercise of options demonstrates the value of the company's equity compensation program.

Negatives

• The sale of a substantial number of shares by a key executive, even if pre-planned, could be perceived negatively by some investors as it reduces the insider's direct equity stake.

Risks

• Market perception of insider selling, even for pre-planned transactions, can sometimes lead to short-term negative sentiment or increased scrutiny of the company's stock performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, potentially leading to minor shifts in sentiment, although the transactions were pre-planned under Rule 10b5-1.

Key Dates

Keywords

NAMS, NewAmsterdam Pharma, Insider Trading, Stock Options, Share Sale, Executive Compensation, Form 4, Beneficial Ownership